Radioimmunotherapy with ibritumomab tiuxetan offers a treatment option for consolidation therapy in previously untreated patients with follicular lymphomas. Administration of Zevalin® after induction chemotherapy prolonged progression free survival in comparison to no further treatment in a phase III trial. Since only the minority of patients included in this trial had received rituximab based regimens prior to ibritumomab tiuxetan, standard practice is not reflected.